Loading...
OTCM
ARSUF
Market cap1.95bUSD
Feb 01, Last price  
18.06
Name

Fagron NV

Chart & performance

D1W1MN
OTCM:ARSUF chart
P/E
—
P/S
—
EPS
1.23
Vol. 1Y
—
Shs. 5Y
0.28%
Rev. 5Y
11.36%
Div Yld LY
—
Div Yld TTM
—
Revenues
952m
+9.20%
276,971,000304,368,000354,506,000391,315,000424,056,000492,330,000547,020,000386,119,000447,056,000472,996,000421,839,000436,934,000471,679,000534,695,000555,971,000573,808,000683,881,000762,991,000871,960,000952,169,000
Net income
91m
+12.99%
12,123,00016,260,00014,900,00019,639,00022,479,00028,140,00043,906,000-32,102,00016,226,000-202,328,000-20,562,00046,658,00042,486,00055,687,00059,601,00061,004,00069,612,00070,547,00080,554,00091,020,000
CFO
128m
+16.73%
17,570,00027,100,00027,741,00039,496,00042,126,00072,147,00067,744,00063,078,000101,696,00073,311,00067,504,00084,247,00073,278,00077,175,00092,953,00078,419,000109,458,000107,379,000109,893,000128,279,000
Dividend
May 19, 20260.4641 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fagron N.V. is a specialized pharmaceutical compounding firm focused on delivering tailored medicinal solutions. The company caters to a diverse range of clients, including hospitals, pharmacies, clinics, and individual patients. Beyond providing direct services, Fagron N.V. actively drives innovation by developing cutting-edge concepts, delivery methods, and specific formulations for pharmaceutical compounding. Its extensive product line includes essential raw materials, specialized tools and equipment, semi-finished goods, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Furthermore, the company supports professional development through the Fagron Academy, offering comprehensive education and training programs for medical prescribers and pharmacists. With a significant global presence, Fagron N.V. operates across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company underwent a name change in January 2015, rebranding from its former identity, Arseus N.V., to Fagron N.V.

Related entities

Subsidiaries (4)
Fagron B.V.
FAGRON CAPITAL
Dr. Kulich Pharma, s.r.o.
FAGRON a.s.

Key people

Independent Chairman of the Board - Representing AHOK BV · since 2017
Rafael Padilla
Chief Executive Officer, Executive Director · since 2018
Karin de Jong
Chief Financial Officer, Executive Director · since 2017
Vera Bakker
Chief Operations Officer · since 2022
Kostas Kouloridas
Area Leader, EMEA · since 2024
Geraldino Neder
Area Leader, Latin America · since 2022
Andrew Pulido
Area Leader, North America · since 2021
Johan Verlinden
Head - Legal and M&A · since 2021
Non-Executive Director · since 2023
Non-Executive Independent Director · since 2022
Neeraj Sharma
Non-Executive Independent Director · since 2022
Non-Executive Independent Director · since 2019
Els Vandecandelaere
Non-Executive Independent Director - Permanent Representative of Els Vandecandelaere LLC · since 2022
IPO date
Oct 05, 2007
Employees
3,035
Domiciled in
BE
Incorporated in
BE
Headquarters & legal address
Venecoweg 20A
Nazareth, VOV 9810
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT